Abstract Details

Title Comparison of Clinical and Laboratory Features of Myasthenia Gravis in Different Ethnic, Gender and Age groups.

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-034

Objective To identify the racial differences in clinical and laboratory features of myasthenia gravis

Background Complex relationships between the clinical and laboratory features of myasthenia gravis (MG) with gender and race has been revealed in prior studies,however the correlation of such differences has been seldom examined. This study is designed to detect racial differences in clinical and laboratory features of MG.

Design/Methods A retrospective cross sectional study of all adults with MG in two major hospitals was done. Demographic data including but not limited to race, age, gender, and serological markers (Acetylcholine receptor (AchR), Muscle specific kinase (MuSK) and Straitional muscle (Str) antibodies) were collected. Statistical analysis with Pearson chi-square test and ANOVA was perfomed. P-values < 0.05 were considered statistically significant.

Results 113 patients were identified. 54.8% of patients were women. 78 patients (69%) had AChR, 10 (8.84%) had MuSK. 52 patients were tested for both antibodies, 6 (5.3%) were double positive and 19 (16.81%) were double negative. 62% of AChR patients were white (p >0.05). Of the 10 MuSK patients, 6 were African American, 3 other races and one white (p< 0.05). 90% of patients with MuSK (9/10) were women (p< 0.05). No statistically significant difference was found in gender distribution of AChR. 64 patients were tested for Str, in 25 with positive results, 76% were African American (p< 0.05). None of the MuSK patients was Str positive. Of 10 MuSK patients,9 had generalized and one had ocular myasthenia (p < 0.05). 65% of AchR patients had generalized MG and 35% had ocular MG (p>0.05).

Conclusions The results of this study support the existence of racial differences in clinical and laboratory features of myasthenia gravis . Further studies of genetic factors affecting clinical features of myasthenia gravis is beneficial.

Authors/Disclosures
Shabnam Pakneshan, MD (henry Ford Medical group) PRESENTER	No disclosure on file
Kamal Shouman, MD (Mayo Clinic)	Dr. Shouman has nothing to disclose.
Sara Razmjou-Schwarz, MD (Mclaren Macomb hospital)	No disclosure on file
Robert P. Lisak, MD, FAAN (Wayne State Univ Sch of Med, Dept of Neuro)	Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argnex. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Bridge Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alivar Therapeutics. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ANI Pharmaceuticals. Dr. Lisak has received personal compensation in the range of $0-$499 for serving as a Consultant for Coleman Research. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tedus Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for COUR Pharma. The institution of Dr. Lisak has received research support from NINDS. The institution of Dr. Lisak has received research support from Argenx. The institution of Dr. Lisak has received research support from Ra Pharmaceuticals. Dr. Lisak has received publishing royalties from a publication relating to health care. Dr. Lisak has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��